The use of levofloxacin in the treatment of respiratory tract infection.
Increasing resistance among the common respiratory pathogens has encouraged assessment of alternative agents, for example, levofloxacin. Unlike earlier quinolones, levofloxacin has excellent activity against Streptococcus pneumoniae, including strains resistant to penicillin. Clinical trials show levofloxacin to be as effective as cephalosporins in acute exacerbation of chronic bronchitis and as effective as co-amoxiclav, cephalosporins or amoxycillin in community-acquired pneumonia. Levofloxacin is rarely associated with serious adverse events. Nausea, diarrhea, headache and rash are the most common adverse events but are observed less frequently than with some other new quinolones.
Shah
P M
PM
Zentrum für Innere Medizin, Infektiologie, Klinikum der J.W. Goethe Universität, Frankfurt am Main, Germany.
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002908:Chronic Disease; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin